GTC
UROV

Ghost Tree Capital’s Urovant Sciences Ltd. UROV Stock Holding History

Ghost Tree Capital’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-300,000
Closed -$1.98M – 50
2018
Q4 		$1.98M Hold
300,000
– – 0.72% 33
2018
Q3 		$3.6M Buy
+300,000
New +$3.55M 0.77% 36

Other funds holding UROV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ghost Tree Capital's UROV Position: Q1 2019 in Review

Ghost Tree Capital sold out of Urovant Sciences Ltd. (UROV) in Q1 2019, closing a stake of 300,000 shares — an estimated $1.98M sold.

Ghost Tree Capital first reported a position in UROV in Q3 2018 and held it in 2 quarters. The position peaked at $3.6M in Q3 2018. 21 funds tracked by Wall St. Rank hold UROV as of Q1 2019.

  • Ghost Tree Capital reported no remaining Urovant Sciences Ltd. position as of Q1 2019 after selling out during the quarter.
  • Ghost Tree Capital sold 300,000 Urovant Sciences Ltd. shares in Q1 2019, an estimated $1.98M.
  • Ghost Tree Capital first reported a position in Urovant Sciences Ltd. in Q3 2018 and held it in 2 quarters.
  • Ghost Tree Capital's Urovant Sciences Ltd. position peaked at $3.6M in Q3 2018.
  • 21 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q1 2019.

Based on Ghost Tree Capital's 13F filing for Q1 2019, filed 15 May 2019.